Precis This study offers a novel, high throughput method to screen for small molecules inhibitors of miRNA maturation, and presents an inhibitor of oncomir miR-21 maturation as a candidate antitumor drug.
Introduction
MicroRNAs (miRNAs) are a class of evolutionarily conserved, small non-coding RNAs that regulate fundamental cellular processes through the modulation of gene expression (1, 2) . The biogenesis of microRNAs begins with the transcription of primary transcripts (pri-miRNAs) that undergo further processing within the nucleus resulting in a hairpin intermediate of approximately 70 nucleotides (pre-miRNA). The pre-miRNA is then transported out of the nucleus to the cytoplasm and Dicer, an RNaseIII, removes the "terminal loop region," or pre-element (preE), to yield a 22 nt mature miRNA duplex. After duplex separation, the guide strand, or mature miRNA, is incorporated into an RNA-induced silencing complex (RISC) that participates in mRNA degradation and/or translational suppression (3, 4) .
Tremendous progress has been made during the last few years to identify novel, tumor-associated microRNAs, which are known to modulate many biological pathways related to cancer initiation, progression, metastasis and therapy resistance (5) (6) (7) . The aberrant expression of microRNAs is deemed to be a notable molecular hallmark of human diseases. miR-21 was one of the first miRNAs detected in the human genome, and it has been validated to be overexpressed in many different types of human cancers, such as glioblastomas (8) , gastric tumors (9) , breast cancers (10) , and colon cancers (11) . Thus, targeting miR-21 and modulating its activity is emerging as a promising therapeutic option and opens a new mode of cancer therapy.
To date, biochemically based tools for the sequence-specific inhibition of miRNA (12) . Although satisfactory results have been reported, there are challenges implicated in the delivery of these non-small molecule agents, and their pharmacodynamic and pharmacokinetic properties are not ideal for the treatment applications (13) . Based on these observations, the discovery of novel and potent small molecules targeting miRNA is needed, and one must take into account both the 3D structure of miRNAs and the thermodynamics of miRNA-small molecule interactions (14) .
Recently, in silico 3D structure prediction has undergone significant advances due to the availability of new experimental data and enhanced computer power and modeling methodologies (15) . MC-Fold/MC-Sym, an RNA-structure-prediction program, has been successfully used to accurately predict the double-helix region of several pre-miRNAs, such as let-7c, miR-19, and miR-29a (16) . Here, we propose a new high-throughput screening method for small molecules targeting miR-21 based on the 3D structure of the Dicer binding site on pre-miR-21 by integrating the MC-Fold/MC-Sym and AutoDock programs (17) .
By screening a small chemical compound library, we identified a specific small molecule inhibitor of miR-21, AC1MMYR2, which directly blocked Dicer's ability to process pre-miR-21 to mature miR-21. Furthermore, we determined that 
Materials and methods

Molecular modeling
The MC-Fold/MC-Sym pipeline is a web-hosted service for RNA secondary and tertiary structure prediction. The pipeline consists of uploading RNA sequence to MC-Fold, which outputs secondary structures that are directly input to MC-Sym, which outputs tertiary structures. Pre-miRNA sequences were obtained from the miRBase database (http://microrna.sanger.ac.uk/sequences/). The hairpin loop of the pre-miRNA was chosen to predict the 3D structure using the MC-Fold/MC-Sym pipeline described previously. Energy optimization was further performed on the 3D model using the TINKER Molecular Modeling Package (http://dasher.wustl.edu/tinker/).
Preparation of the receptor structure
For docking with AutoDock, polar hydrogen atoms, Kollman united charges, and solvent parameters were applied to the receptor using pmol2q script version 4 were prepared from the .pdb files using the prepare_ligand.py script.
Molecular docking and post-docking analysis
High-throughput docking-based virtual screening was performed using MDA-MB-231(PTEN wt/P53 mut) and SGC7901 (P53 mut). The cells of MDA-MB-231 were maintained in 1640 (Gibco), whereas the others were maintained in DMEM (Gibco) supplemented with 10% FBS (Gibco), 2 mM glutamine (Sigma), 100 ȝg/ml penicillin (Sigma), 100 ȝg/ml streptomycin (Sigma), and incubated at 37°C in 5% CO 2 . AC1MMYR2 was obtained from the NCI diversity dataset and diluted to the indicated concentrations in cell culture media.
Research. wild type and mutant plasmids were purchased from GenePharma Co., Ltd.
(Shanghai, China), and transfections were performed as previous described (18) .
Real-time PCR and Western blot analyses
Real-time PCR and Western blot analyses were performed according to the manufacturer's instructions as previously described (19) . For Western blot, the band density of specific proteins was quantified after normalization with the density of GAPDH.
Fluorescence in situ hybridization, immunofluorescence and cell biological functions assays
Fluorescence in situ hybridization (FISH) detection of miR-21 was performed as previously described (20) . Immunofluoresence staining was performed using antibodies against E-cadherin, N-cadherin, ȕ-catenin, and ZEB1/2 (1:100 dilutions; Cell Signaling Technology), and the cells were visualized using FV-1000 laser scanning confocal microscopes. The assays for colony formation, cell cycle, apoptosis and transwell were reported previously (21) . Caspase 3/7 activity was measured using Caspase-Glo 3/7 reagent (Promega).
Orthotopic nude mouse models and treatment
BALB/c-A nude mice at 4 weeks of age were purchased from the Animal Center at the Cancer Institute at Chinese Academy of Medical Science. To establish intracranial gliomas, 0.5 × 10 5 U87 glioblastoma cells transduced with luciferase lentivirus were implanted stereotactically (22) . Seven days postimplantation, the 
H&E staining, TUNEL staining and immunohistochemistry analysis
The paraffin-embedded tissue sections were used for H&E staining, TUNEL staining and immunohistochemistry analysis as previous described (21) . For immunohistochemistry analysis, the sections were incubated with primary antibodies
(1:100 dilutions) overnight at 4°C, followed by a biotin-labeled secondary antibody
(1:100 dilutions) for 1 h at 37°C, and then incubated with ABC-peroxidase and diaminobenzidine (DAB), counterstained with hematoxylin, and visualized using a 
Results
Discovery of AC1MMYR2, a potent and selective inhibitor of miR-21
To screen small molecule inhibitors of miR-21, we proposed a high-throughput screening method for small molecules targeting miR-21 based on the 3D structure of the Dicer binding site on pre-miR-21. A schematic representation of our workflow is illustrated in Fig. S1A . The sequence of the pre-miR-21 hairpin loop (Dicer binding site on pre-miR-21) was generated from the miRBase database and then input to the MC-Fold/MC-Sym pipeline to construct a 3D model ( Fig. S1B and Fig. S1C ). For this model, we analyzed energy optimization using TINKER. Next, we performed high-throughput molecular docking for pre-miR-21 against the 1,990 NCI diversity compounds using the AutoDock program (Table S1 ).The specific docking process can be visualized in Video S1. Here, our dockings revealed 48 compounds with high binding affinity (indicated by DeltaG, Table S2 ). The top 5 were further assessed for miR-21 inhibition efficacy in four human epithelial cancer cells (U87 and LN229 glioblastomas cells, MCF-7 breast cancer cells, and SGC7901 gastric cancer cells).
Both the compound AC1MMYR2 (also known as NSC211332) and the As-miR-21
presented strong inhibition of miR-21 expression in all cancer cells (Fig. S2) . The selectivity and specificity of AC1MMYR2 interruption miR-21 generation was further assessed by measuring intracellular miRNA levels using Real-time PCR (Fig. 1F ). We randomly chose 11 miRNAs: miR-23b, miR-566, miR-27b, miR-222, miR-524-5p, let-7i, miR-218, miR-1280, miR-200a/b and miR-181d. After 6 h of treatment, the expression levels of 11 miRNAs were virtually unchanged in the four cell lines. 24 h later, the expression levels of miR-23b, miR-566, miR-27b, miR-222 and miR-524-5p were significantly reduced, whereas the expression levels of let-7i, 
AC1MMYR2 specifically blocks Dicer processing pre-miR-21 to mature miR-21
Because the identification of small molecule inhibitors targeting miR-21 was based on the 3D structure of the Dicer binding site on pre-miR-21, we evaluated whether the pre-miR-21 expression was changed. As expected, the level of pre-miR-21 increased in a time-dependent manner in all cell lines ( Fig. 2A) . Notably, plasmid after the compound treatment in U87 and MCF-7 cells, respectively (Fig. 2C ).
This indicated that miR-21 mimics increased the mature miR-21 levels, whereas the PTRE-miR-21(FL) plasmid only induced pri-miR-21 and pre-miR-21 expression levels. These data confirmed that AC1MMYR2 blocked Dicer processing at the binding site of pre-miR-21 to repress the mature miR-21 generation.
To verify the potential site of Dicer binding on pre-miR-21 that AC1MMYR2 acts on, we constructed 3 pre-miR-21 point mutation plasmids, MUT1 (base "a" was deleted), MUT2 (base "c" was switched to "t") and MUT3 (base "c" was switched to "g") ( Fig. 2D) , and a pre-miR-21 wild type plasmid (WT). After transfection with the 4 plasmids in U87 and MCF-7 cells, pre-miR-21 expressions were all upregulated in the transfected groups, compared with Control. Moreover, there was no statistic significance between MUTs and WT groups in pre-miR-21 overexpression. However, overexpression of mature-miR-21 was detected merely in WT group; there were no significant changes in MUTs groups in comparison with Control (Fig. 2E) . Therefore, we concluded that the point mutations at Dicer binding site on pre-miR-21 disturbed Dicer processing pre-miR-21 to mature miR-21.
To analysis whether these point mutations also influenced AC1MMYR2 action, we created the 3D structure of pre-miR-21 hairpin loop with such mutations. After AC1MMYR2 respectively docking with these 3D models (Fig. 2F) , the estimated free energy of binding was -5.15 kcal/mol, -4.94 kcal/mol and -5.84 kcal/mol, whereas the binding affinity of WT was -12.04 kcal/mol (Table S2) 
affinity and thus weaken its activity. Therefore, AC1MMYR2 probable specifically blocked the Dicer binding site on pre-miR-21. Besides, we proved that AC1MMYR2 selectively targeted tumor cells with miR-21 high expression (Fig. S3) , which also showed the specificity of AC1MMYR2 towards miR-21 to some extent.
AC1MMYR2 represses mature miR-21 generation via Dicer-dependent expression
As suggested, Dicer is a central enzyme in microRNA processing (24) . To further investigate whether the AC1MMYR2 specific interruption of Dicer processing correlated with its expression, we reduced Dicer levels using an siRNA sequence in U87 and MCF-7 cells. Dicer expression was greatly reduced after transfection relative to the Control and Scramble (Fig. 3A) . Meanwhile, cells transfected with the Dicer siRNA sequence alone reduced the mature miR-21expression; however, AC1MMYR2 retreatment after transfection did not induce a more significant decrease (Fig. 3B ).
Confocal microscopy also displayed miR-21 staining to be attenuated in the cytoplasm of siRNA transfected cells, whereas no obvious change occurred after compound retreatment (Fig. 3C) . Taken together, these data indicate that AC1MMYR2 functions are dependent on Dicer expression. The compound could not effectively repress mature miR-21 generation when Dicer levels were low, and the underlying mechanism demands intensive study.
AC1MMYR2 inhibits tumor cell proliferation and promotes apoptosis
Excessive epithelial cell proliferation is a hallmark of the initiation and early growth of primary epithelial cancers (25) . After confirming the target of 
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AC1MMYR2 action, we went on to test the compound effect on tumor cell biological characteristics, especially proliferation and apoptosis. FISH assessment displayed that miR-21 expression was remarkably decreased after AC1MMYR2 treatment in U87, MCF-7 (Fig. 4A ), LN229 and SGC7901 cells (Fig. S4A) . Moreover, reduced miR-21 resulted in decreased colony formation rates (Fig. 4B and Fig. S4B) , and flow cytometry analysis demonstrated that the cell-cycle was blocked in the G0/G1 phase ( Fig. 4C and Fig. S4C ).
GO analysis for the biologic processes was performed on the 534 genes whose expression was significantly altered in response to 6-hour treatment with AC1MMYR2 in U87 glioma cells (Table S3) . "Regulation of cell proliferation" was the sixth term on the top 20 most statistically significant (by P value) GO categories (Table S4) . Meanwhile, KEGG pathway analysis revealed that there were 14 different pathways corresponding to the target genes, of which "Pathways in cancer" was most significant (P=5.7E-4, Table S5 ).
Annexin V/PI staining was performed to quantify the apoptosis induced by the compound. Compared to the DMSO group, the AC1MMYR2 treatment caused more apoptosis, and the apoptosis rates were approximately 15% (Fig. 4D and Fig. S4D ).
Specifically, the cells that respond to AC1MMYR2 also had higher caspase 3/7 activities ( Fig. 4E and Fig. S4E ). Based on the above findings, we conclude that AC1MMYR2, as a miR-21 inhibitor, is potent at suppressing tumor cell growth and survival.
AC1MMYR2 suppresses tumor cell migration and invasion
Research. Migration and invasion are crucial biological characteristics for tumor cell metastasis (26) , and one mission-critical step in the metastatic cascade is the process of EMT (27) . To investigate whether AC1MMYR2 could impact the migration and invasiveness of tumor cells, transwell assays and EMT associated markers expression levels were detected. As shown in Fig. 5A and Fig. S5A , fewer AC1MMYR2 treated tumor cells invaded across the pre-coated matrigel membrane compared to the DMSO treated cells. In addition, Western blot analysis indicated that E-cadherin expression was increased, whereas N-cadherin, ȕ-catenin, ZEB1, ZEB2 and MMP9 expression levels were reduced after compound treatment ( Fig. 5B and Fig. S5B ).
Importantly, because the activities of transcriptional factors are usually associated with their subcellular location, we further assessed the distribution of the proteins mentioned above by confocal microscopy. As displayed in Fig. 5C and Fig.   S5C , E-cadherin plasmalemmal expression was upregulated after AC1MMYR2 treatment, accompanied with a decrease in N-cadherin plasmalemmal expression.
Moreover, in the DMSO group, ȕ-catenin expression was mainly localized to the nucleus; however, after compound treatment, nuclear ȕ-catenin expression was reduced and translocated to the cytoplasm. ZEB1 and ZEB2 nuclear expression levels were also reduced in the compound-treated group.
Antitumor efficacy of AC1MMYR2 in orthotopic models
Our in vitro study suggested that AC1MMYR2 was a potent miR-21 inhibitor that suppressed tumor cell growth and invasion. To further confirm this, a proof-of-principle experiment was employed using an orthotopic glioma model, two For U87 glioma intracranial model, BLI demonstrated tumor growth stasis in the AC1MMYR2-treated group compared to the DMSO-treated tumors and on day 14, a statistically significant difference in tumor volume appeared between the two groups ( Fig. 6A and B) . The body weights of the mice in the treatment group increased constantly during their overall survival time, whereas the DMSO treated mice lost in weight (Fig. 6C) . Only 2 mice in the AC1MMYR2 treatment group died on day 47, whereas there were no mice alive in the DMSO treatment group (Fig. 6D) .
Furthermore, H&E staining displayed that the tumors formed by DMSO treated cells exhibited extensive branch-like growing patterns and vessels that spread into the surrounding tissue. By contrast, AC1MMYR2-treated cells formed oval-shaped tumors with smooth margins and a non-invasive front, further validating that the invasive behavior of glioma could be suppressed by AC1MMYR2. Meanwhile, MiR-21 expression was markedly decreased, but apoptotic nuclei were increased in the compound treatment group (Fig. 6E) .
We also stained for an astrocyte differentiation marker, GFAP, existed during the process of differentiation (28) . A significant increase in GFAP expression was observed in cells treated with AC1MMYR2, which indicated that the malignancy of glioblastomas was attenuated by AC1MMYR2 to a certain extent. Besides, the expressions of PCNA, Ki67, CyclinD1, ȕ-catenin, ZEB1/2 and MMP9 decreased, whereas RECK, PDCD4 and E-cadherin expression levels were simultaneously increased in AC1MMYR2-treated group relative to the DMSO-treated group (Fig. 6F) .
Furthermore, H&E staining of multiple tissues showed no discernible toxicity of AC1MMYR2, including in the liver and kidney (Fig. S6) .
As previously reported, MDA-MB-231 breast cancer cells are highly metastatic compared with MCF-7 cells (29) . AC1MMYR2 also inhibited MDA-MB-231 cells proliferation and invasion in vitro (Fig. S7-9 ). To further monitor treatment efficacy in live animals, we constructed not only a MCF-7 orthotopic breast cancer model but also a highly metastatic MDA-MB-231 orthotopic model. BLI demonstrated tumor growth stasis in the AC1MMYR2-treated group compared to the DMSO-treated tumors and on day 7, a statistically significant difference appeared in tumor volume (Fig. 7A-C) . At the termination of the study, the tumor weights were significantly different between the two groups (Fig. 7D) , and we also found lung metastasis in MDA-MB-231 orthotopic model but no organ metastasis in MCF-7 orthotopic model. AC1MMYR2 treatment significantly reduced the MDA-MB-231 cells lung metastasis (Fig. 7E) . Meanwhile, tumors derived from DMSO-treated groups revealed more nuclei and darker chromatin staining compared to the AC1MMYR2 treatment group, as determined by H&E staining. The expression levels of PTEN, RECK, PDCD4 and E-cadherin, and apoptotic nuclei were increased, whereas miR-21, PCNA, CyclinD1, Ki67, N-cadherin, ȕ-catenin, ZEB1/2, and MMP9 expressions were significantly reduced in tumor specimens from the compound treatment group (Fig. S10A and B) .
In summary, our in vivo preclinical efficacy trials showed a remarkable antitumor effect of AC1MMYR2 in both glioblastoma and breast cancer orthopotic models. 
In this study, we constructed a 3D model of the pre-miR-21 hairpin loop and Dicer binding domain. By high-throughput molecular docking to the 1,990 NCI diversity compounds and further miR-21 inhibition analysis, AC1MMYR2 was identified as a specific miR-21 small molecular inhibitor, which specifically blocked Dicer processing pre-miR-21 to mature-miR-21. Recently, a transcriptional regulatory circuit involving miR-21, PTEN-AKT pathway and NF-kB-IL-6-STAT3 positive feedback loop was reported in cancers. Inhibition of miR-21 expression increases the PTEN expression, thereby reduces the AKT activity and subsequent inhibits NF-kB activity and IL-6 production. Moreover, STAT3, a transcription factor activated by IL-6, directly activates miR-21 (36) . Based on these, we supposed that overexpression of PTEN induced by AC1MMYR2 inhibited the AKT activity and then suppressed NF-kB-IL-6-STAT3 positive feedback loop PTEN and pSTAT3 expressions were presented in Fig. 1E , ultimately resulted in the inhibition of pri-miR-21 transcription.
Thus, we established a positive feedback loop between STAT3 and pri-miR-21, which certainly required further investigation in future.
PTEN, PDCD4 and RECK, which are considered to be associated with tumor cell survival, proliferation and invasion (37, 38, 20) , were upregulated after AC1MMYR2 treatment. More importantly, altered expression levels of a set of miRNAs, such as miR-200a/b and miR-181d, were observed after AC1MMYR2 treatment. It is reported that miR-21 overexpression in epithelial cancers facilitates the initiation of EMT (39, 40) . EMT is an evolutionarily conserved process that and elevated resistance to apoptosis (41) . Several transcriptional factors, including Snail1/2, ZEB1/2, and Slug have been reported to be involved in EMT (42) . Based on the preceding observations, we indicated that miR-200a directly interacted with ȕ-catenin and ZEB1/2 to reverse EMT in U251 glioblastoma and SGC7901 gastric cancer cells (43) and that ȕ-catenin and ZEB1 were also functional targets of miR-181d (unpublished data). In addition, PTEN inhibition of ȕ-catenin activation via the downregulation of pAKT has been verified in our previous studies (8, 44) .
Thus, altered miRNAs and PTEN expression levels may impact the EMT process via the regulation of ȕ-catenin, ZEB1 and ZEB2. To further confirm this, we detected epithelial and mesenchymal markers and EMT-related transcriptional factor expressions after compound treatment.
In many cancer types, the loss of E-cadherin coincides with a gain of expression of the mesenchymal cadherin, N-cadherin. This "cadherin switch" is considered to be a hallmark of EMT (45) . However, it was reported that epithelial cell adhesion complexes reorganized and cell proliferation was suppressed upon exogenous expression of the E-cadherin gene (46) ; simultaneously, the cells that passed through EMT lost their mesenchymal phenotype (41) . Increased expression of E-cadherin was also well-established to be an antagonist of invasion and metastasis (47) . cytoplasm, it can reverse the migratory characteristics of the cell by reestablishing interactions with E-cadherin and forming cell-cell adhesions (48) . Zinc finger E-box binding homeobox proteins, ZEB1 and ZEB2, which are well-known transcriptional repressors of E-cadherin, are both implicated in EMT and tumorigenesis (49) . Thus, cells overexpressing ȕ-catenin, ZEB1 and ZEB2 cause them to be more susceptible to EMT. In our study, in combination with upregulated E-cadherin, AC1MMYR2
significantly reduced the nuclear expression levels of ȕ-catenin and ZEB1/2, as well as the expression of MMP9, thereby reversing EMT in the epithelial cancers. This may be another underlying mechanism of AC1MMYR2 to facilitate the suppression of the tumor growth and invasion.
Moreover, it remains highly interesting that an astrocyte differentiation marker, GFAP, had its expression level induced in U87 intracranial samples after AC1MMYR2 treatment. A recent study observed the co-expression of GFAP/Slug and GFAP/Twist in mesenchymal areas of glioscarcoma and indicated that it may represent an initial step in glial-mesenchymal transition (50) . Based on these observations, we considered that a potential association may exist between GFAP levels and EMT. Increased GFAP expression, with the simultaneous reduction of mesenchymal marker expression levels induced by AC1MMYR2, perhaps indicated a reacquisition of epithelial characteristics, which certainly requires further investigations.
In our present study, we propose a novel high-throughput screening method for small molecules targeting miRNAs and identify a potent and specific miR-21 inhibitor, 
